Novel Therapeutic Perspectives for Wet Age-Related Macular Degeneration: RGD-modified Liposomes Loaded with 2-Deoxy-d-glucose As a Promising Nanomedicine
XiRui Chen,SiWei Liu,MoXin Chen,Ni,Rong Zhou,YiQi Wang,Yang Xu,YuanHui Wang,HuiQin Gao,DanDan Zhang,ZhiMin Tang,Qin Shu,Jing Zhang,Lin Li,YaHan Ju,Ping Gu
DOI: https://doi.org/10.1016/j.biopha.2024.116776
IF: 7.419
2024-01-01
Biomedicine & Pharmacotherapy
Abstract:Choroidal neovascularization (CNV), characterized as a prominent feature of wet age-related macular degeneration (AMD), is a primary contributor to visual impairment and severe vision loss globally, while the prevailing treatments are often unsatisfactory. The development of conventional treatment strategies has largely been based on the understanding that the angiogenic switch of endothelial cells is dictated by angiogenic growth factors alone. Even though treatments targeting vascular endothelial growth factor (VEGF), like Ranibizumab, are widely administered, more than half of the patients still exhibit inadequate or null responses, emphasizing the imperative need for solutions to this problem. Here, aiming to explore therapeutic strategies from a novel perspective of endothelial cell metabolism, a biocompatible nanomedicine delivery system is constructed by loading RGD peptide-modified liposomes with 2-deoxy-D-glucose (RGD@LP-2-DG). RGD@LP-2-DG displayed good targeting performance towards endothelial cells and excellent in vitro and in vivo inhibitory effects on neovascularization were demonstrated. Moreover, our mechanistic studies revealed that 2-DG interfered with N-glycosylation, leading to the inhibition of vascular endothelial growth factor receptor 2 (VEGFR2) and its downstream signaling. Notably, the remarkable inhibitory effect on neovascularization and biocompatibility of RGD@LP-2-DG render it a highly promising and clinically translatable therapeutic candidate for the treatment of wet AMD and other angiogenic diseases, particularly in patients who are unresponsive to currently available treatments.